skip to Main Content

News

Press Release: FDA Grants Orphan Drug Designation for PVSRIPO for the Treatment of Advanced Melanoma

Istari Oncology Announces FDA Grants Orphan Drug Designation for PVSRIPO for the Treatment of Advanced…

read more

Press Release: Istari Announces 1st Patient in LUMINOS-101 Trial of PVSRIPO with Pembrolizumab for rGBM

Istari Oncology Announces First Patient Dosed in the LUMINOS-101 Phase 2 Clinical Trial of PVSRIPO…

read more

Partner News: UH Seidman Cancer Center Opens New Trial with PVSRIPO

From the office of University Hospitals Seidman Cancer Center: UH Seidman Cancer Center Opens New…

read more

Press Release: Istari to Open LUMINOS-102 Trial in Treatment-Refractory Melanoma

Istari Oncology Announces FDA Clearance of New IND to Open LUMINOS-102: PVSRIPO with and without…

read more

Press Release: Istari Oncology Presents Data from Phase 1 Melanoma Study

For the full poster on the Phase 1 trial click the button below.

read more

Published Research in Nature Communications: Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity

Journal authors for the below study: Mubeen M. Mosaheb, Elena Y. Dobrikova, Michael C. Brown,…

read more

Published Research in Science Advances: CReP mediates selective translation initiation at the endoplasmic reticulum

Journal authors for the below study: Jonathan P. Kastan, Elena Y. Dobrikova, Jeffrey D. Bryant,…

read more

Announcing the new Istari Oncology website

Welcome to our new website; we invite you to look around. Please contact us if…

read more

Istari Oncology Announces NEJM Publication of Phase 1 Trial Results in Patients with Recurrent Glioblastoma Treated with PVSRIPO

21% Overall Survival at 24 Months and 36 Months, Compared to 14% and 4% in…

read more
Back To Top
×Close search
Search